These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 23200706)

  • 1. Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience.
    Delia M; Pastore D; Mestice A; Carluccio P; Perrone T; Gaudio F; Ricco A; Sgherza N; Albano F; Specchia G
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):495-9. PubMed ID: 23200706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation.
    Pastore D; Delia M; Mestice A; Carluccio P; Perrone T; Gaudio F; Curci P; Rossi AR; Ricco A; Specchia G
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):887-93. PubMed ID: 22062803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation.
    Delia M; Carluccio P; Mestice A; Chiusolo P; Metafuni E; Bellesi S; Arpinati M; Milone GA; Martino M; Mazza P; Ingrosso C; Vacca A; Saporiti G; Zallio F; Attolico I; Pastore D; Specchia G; Albano F; Musto P
    Transplant Cell Ther; 2021 Nov; 27(11):918.e1-918.e9. PubMed ID: 34403789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation in Iran.
    Alimoghaddam K; Ghaffari H; Foroughi F; Chardouli B; Sanaat Z; Bahar B; Mousavi A; Iravani M; Ghavamzadeh A
    Arch Iran Med; 2006 Apr; 9(2):99-103. PubMed ID: 16649348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral Blood Stem Cell Transplantation for the Treatment of Acute Leukemia-A Retrospective Study in China.
    Tong J; Xuan L; Sun Y; Huang D; Liu H; Zheng C; Zhu X; Tang B; Song K; Zhang X; Zhang L; Yao W; Lin D; Liu Q; Sun Z
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1541-1548. PubMed ID: 28499936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasia.
    Bertz H; Spyridonidis A; Ihorst G; Engelhardt M; Grüllich C; Wäsch R; Marks R; Finke J
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):894-902. PubMed ID: 22108569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
    Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA
    J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis.
    Novitzky N; Thomas V; du Toit C; McDonald A
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):875-84. PubMed ID: 20870030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Nadal E; Garin M; Kaeda J; Apperley J; Lechler R; Dazzi F
    Leukemia; 2007 Mar; 21(3):472-9. PubMed ID: 17215853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
    Ringdén O; Labopin M; Solders M; Beelen D; Arnold R; Ehninger G; Milpied N; Niederwieser D; Hamladji RM; Kyrcz-Krzemien S; Ganser A; Socié G; Stelljes M; Volin L; Craddock C; Mohty M;
    Transplantation; 2014 Sep; 98(5):569-77. PubMed ID: 24798307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome following second allogeneic hematopoietic cell transplantation: A single-center experience.
    Aljasem HA; Messner HA; Lipton JH; Kim DDH; Viswabandya A; Thyagu S; Deotare U; Michelis FV
    Eur J Haematol; 2018 Mar; 100(3):308-314. PubMed ID: 29240253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
    Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.